Have a feature idea you'd love to see implemented?
Let us know!
ETNB 89bio Inc
Price (delayed)
$8.38
Market cap
$889.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.91
Enterprise value
$835.5M
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is
Highlights
The company's net income has shrunk by 128% YoY and by 65% QoQ
ETNB's EPS has dropped by 61% year-on-year and by 48% since the previous quarter
Key stats
What are the main financial stats of ETNB
Market
Valuations
Earnings
Shares outstanding
106.13M
Market cap
$889.34M
Enterprise value
$835.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.35
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$279.69M
EBITDA
-$279.02M
Free cash flow
-$280.54M
Per share
Balance sheet
Liquidity
EPS
-$2.91
Free cash flow per share
-$2.62
Book value per share
$3.57
Revenue per share
$0
TBVPS
$4.28
Total assets
$458.3M
Total liabilities
$80.2M
Debt
$37.57M
Equity
$378.1M
Working capital
$417.08M
Debt to equity
0.1
Current ratio
11.66
Quick ratio
10.83
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.2%
Return on equity
-59.6%
Return on invested capital
-83%
Return on capital employed
-66.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETNB stock price
How has the 89bio stock price performed over time
Intraday
5.01%
1 week
-4.23%
1 month
3.08%
1 year
10.41%
YTD
-24.98%
QTD
13.24%
Financial performance
How have 89bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$303.86M
Net income
-$288.96M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 128% YoY and by 65% QoQ
The company's operating income has shrunk by 124% YoY and by 59% QoQ
Growth
What is 89bio's growth rate over time
Valuation
What is 89bio stock price valuation
P/E
N/A
P/B
2.35
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ETNB's EPS has dropped by 61% year-on-year and by 48% since the previous quarter
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 1.8 but 2.1% less than its 5-year quarterly average of 2.4
The equity is down by 27% since the previous quarter and by 8% year-on-year
Efficiency
How efficient is 89bio business performance
89bio's return on equity has shrunk by 71% YoY and by 68% QoQ
ETNB's return on assets has dropped by 69% year-on-year and by 66% since the previous quarter
The ROIC has contracted by 48% from the previous quarter and by 25% YoY
Dividends
What is ETNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETNB.
Financial health
How did 89bio financials performed over time
ETNB's total liabilities has soared by 61% YoY and by 19% QoQ
89bio's quick ratio has decreased by 39% YoY and by 15% from the previous quarter
89bio's debt is 90% lower than its equity
ETNB's debt to equity has soared by 100% from the previous quarter and by 67% YoY
89bio's debt has surged by 51% YoY and by 37% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.